GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been assigned an average recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.20.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a report on Thursday, February 27th.

GeoVax Labs Trading Down 3.0 %

GOVX stock opened at $1.31 on Friday. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18. The firm has a 50-day moving average of $1.75 and a two-hundred day moving average of $2.21.

Institutional Trading of GeoVax Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in GOVX. Virtu Financial LLC acquired a new stake in shares of GeoVax Labs during the 3rd quarter worth approximately $97,000. Geode Capital Management LLC increased its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $29,000. Finally, Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $104,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.